Program
mifomelatide
Its studies are mostly in Colorectal Neoplasms · Cachexia, led by Endevica Bio.
Furthest: phase 2, since Mar 25, 20252 company-led studies, 1 open or runningNext primary completion: Oct 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Endevica Bio | 21 open or running | phase 2since Mar 25, 2025 | Jul 28, 2022 | Oct 2027phase 2 · NCT06937177 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 28, 2022First study: phase 1 study in CachexiaFirst studyNCT05529849 · 76 enrolled · United States
- Mar 25, 2025Phase 2 study in Colorectal NeoplasmsNCT06937177 · 120 planned · United States, Canada
Ahead
- Oct 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT06937177
TargetBeta
“A synthetic cyclic peptide antagonist of melanocortin receptor 3 (MC3R) and melanocortin receptor 4 (MC4R), ”NCIt, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06937177Colorectal Neoplasms · United States, Canada | 2 | Recruiting | Oct 2027 | 120 |
| NCT05529849Cachexia · United States | 1 | Completed | Dec 12, 2022 | 76 |
How it is read
Names in the registry
- “TCMCB07”, 2 entries
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 1 study
- Cachexia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.